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To investigate azole resistance in clinical Aspergillus iso-
lates, we conducted prospective multicenter international 
surveillance.	 A	 total	 of	 3,788	 Aspergillus isolates were 
screened	 in	22	centers	 from	19	countries.	Azole-resistant	
A. fumigatus	was	more	frequently	found	(3.2%	prevalence)	
than previously acknowledged, causing resistant invasive 
and noninvasive aspergillosis and severely compromising 
clinical use of azoles.
Azole resistance is increasingly recognized as a prob-lem in aspergillus diseases (1). Within the Aspergillus 
fumigatus species complex, new sibling species have been 
reported to cause invasive aspergillosis; these species are 
generally intrinsically less susceptible than A. fumigatus 
sensu strictu to azole compounds (2). Acquired resistance to 
azoles in A. fumigatus has become a public health concern 
because of the presumed fungicide-driven route of resistance 
selection and the associated risk for geographic migration. 
Surveillance studies show that, in areas to which Aspergillus 
is endemic, the environmental route of resistance selection 
contributes to >90% of resistance mechanisms in azole-re-
sistant aspergillus diseases (1,3). Azole resistance has been 
observed in patients with no recent history of azole therapy, 
and the mortality rate for patients with azole-resistant inva-
sive aspergillosis was 88% (3).
The Study
Our objective was to investigate the prevalence of azole 
resistance in clinical Aspergillus isolates. A multicenter in-
ternational surveillance network was established (Surveil-
lance Collaboration on Aspergillus Resistance in Europe 
[SCARE-network]), comprising 22 centers from 19 coun-
tries (18 European and 4 non-European sites) (Figure 1). 
To detect azole-resistant A. fumigatus, we developed a phe-
notypic screening-method using a 4-well plate format with 
agar supplemented with itraconazole, voriconazole, and 
posaconazole (4). Each center was asked to screen for azole 
resistance for 12 consecutive months. For each screened 
isolate, patient characteristics were registered through an 
online questionnaire, and patients with invasive aspergillo-
sis were classified according to the European Organization 
for the Research and Treatment of Cancer/Mycoses Study 
Group consensus definitions (5).
For every A. fumigatus isolate that grew on any of the 
azole-containing wells, the primary culture isolate was sent 
both to the Radboud University Medical Centre (Nijmegen, 
the Netherlands) and Statens Serum Institute (Copenhagen, 
Denmark) for molecular species identification, susceptibil-
ity testing according to the EUCAST (European Committee 
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DISPATCHES
on Antimicrobial Susceptibility Testing) broth microdilution 
reference method (6), and determination of the full coding 
sequence of both strands of the cyp51A gene and the promot-
er region by PCR amplification. For every resistant isolate, a 
susceptible control isolate was assigned; this control isolate 
was the first susceptible isolate screened on the 4-well plate 
format in the same center after the resistant isolate, and they 
received molecular species identification and susceptibility 
testing according to the EUCAST broth microdilution refer-
ence method (6).
During January 2009–January 2011, a total of 3,788 
Aspergillus isolates were screened for azole resistance by 
using the 4-well plates (Figure 1). Clinical information 
was available from 1,911 patients from 21 centers in 18 
countries. Most (2,941 [77.6%]) isolates were classified 
as A. fumigatus species complex and were recovered from 
1,450 patients. The most common underlying disease was 
chronic lung disease (30.0%), followed by cystic fibrosis 
(22.1%) and hemato-oncologic diseases (12.9%). A total 
of 204 (14.1%) patients had undergone hematopoietic 
stem cell transplantation or solid organ transplantation, 
and 265 (18.3%) had been treated with corticosteroids 
within 3 months before culture of the isolate. A total of 
223 (15.4%) of 1,450 patients had received antifungal 
drugs within 3 months before, or at the time of the posi-
tive culture. For 806 (55.6%) patients, the clinical rele-
vance of the cultured A. fumigatus sc isolate was reported 
(Figure 2).
For 60 A. fumigatus species complex isolates, the re-
sistant phenotype was confirmed in vitro (Table 1). Forty-
seven (78.3%) azole-resistant isolates were identified as 
A. fumigatus sensu strictu. The other 13 azole-resistant 
isolates were identified as A. lentulus (7 isolates), Neosar-
torya pseudofisheri (4 isolates), and N. udagawae (2 iso-
lates). Sequence analysis of the cyp51A gene of A. fumig-
atus showed TR
34
/L98H in 23 (48.9%) azole-resistant A. 
fumigatus isolates (Table 2). All TR
34
/L98H isolates were 
cultured from patients from European centers. In 3 isolates 
from the Netherlands, the TR
46
/Y121F/T289A resistance 
mechanism was found (7).
A total of 60 azole-resistant isolates were recovered from 
46 patients. The overall prevalence of azole resistance among 
patients with A. fumigatus species complex isolates was 3.2% 
(range 0.0%–26.1% among the centers). Azole resistance 
was detected in 11 (57.9%) of 19 participating countries. Ac-
quired resistance in A. fumigatus was found at European sites: 
Austria, Belgium, Denmark, France, Italy, the Netherlands, 
Spain, Sweden, and the United Kingdom. In 5 countries 
(Australia, Germany, Spain, Sweden, and United Kingdom), 
azole-resistant A. fumigatus sibling species were recovered.
From the 46 patients with resistant isolates, 8 patients 
had azole-resistant A. fumigatus sibling isolates, and 38 
had a resistant A. fumigatus isolate. Of these 38 patients, 
19 had an isolate that harbored a fungicide-driven resis-
tance mechanism (i.e., TR
34
/L98H or TR
46
/Y121F/T289A). 
When comparing patients with isolates harboring presumed 
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Figure 1. Study characteristics 
(number	of	isolates/patients	
screened)	from	22	centers	in	19	
countries participating in a study 
of azole resistance in Aspergillus 
fumigatus.	*Period	screened	was	
8 months instead of 1 year in this 
center for unknown reason. †Total 
number of screened patients is 
unknown because this center 
is a reference laboratory that 
does not have access to patient 
characteristics.
Azole	Resistance	in	A. fumigatus
fungicide-driven resistance mechanisms with “non–fungi-
cide driven” resistance mechanisms (i.e., point mutations 
or non–Cyp51A-mediated mechanisms), azole exposure 
differed significantly: 4 (21.1%) of 19 patients with an iso-
late with the fungicide-driven resistance mechanism had a 
history of azole therapy, compared with 16 (84.2%) of 19 
patients with isolates with other or no cyp51A mutations 
(p = 0.001). Of the 195 cases with invasive aspergillosis, 
azole resistance was documented in 10 (5.1%) (3 proven, 
1 probable, and 6 possible infections). Among the patients 
with resistant isolates, 28 patients had documented asper-
gillus disease (online Technical Appendix Table, http://
wwwnc.cdc.gov/EID/article/21/6/14-0717-Techapp1.pdf). 
The case-fatality rate for this cohort was 70%.
Conclusions
Acquired azole resistance in A. fumigatus was detected in 
11 of 17 European centers in 9 countries. Overall preva-
lence of azole resistance was 3.2%; TR
34
/L98H was the 
predominant mechanism of resistance (48.9%) in A. fu-
migatus sensu strictu isolates. This finding substantiates 
our concern that azole resistance is an emerging problem 
in A. fumigatus and that resistance selection in the environ-
ment contributes significantly to azole-resistant aspergillus 
diseases. A predilection of isolates harbored the TR
34
/L98H 
mutation for patients with acute invasive diseases over pa-
tients with aspergilloma and chronic pulmonary aspergillo-
sis. Azole-resistant invasive aspergillosis was documented 
in 5.1% of cases of invasive aspergillosis, which is not low-
er than the percentage of the prevalence of azole resistance 
among the A. fumigatus isolates (3.2%). This finding might 
indicate that resistance does not come with a significant 
fitness cost and that azole-resistant isolates that harbored 
TR
34
/L98H or TR
46
/Y121F/T289A are at least as capable 
of causing invasive aspergillosis as nonresistant wild-type 
isolates. Although the clinical implications of sibling spe-
cies of A. fumigatus are less well understood, our study 
confirms that these species are generally less susceptible 
than A. fumigatus to azole antifungal drugs.
Our study shows that azole resistance is widespread 
in Europe. Azole-resistant A. fumigatus caused aspergillus 
diseases in the patients in our study, and azole resistance 
was associated with a worsened outcome (3). A rapid and 
convenient screening method for resistance is indispens-
able, and centers that care for patients with aspergillus 
diseases should perform surveillance to determine their 
local epidemiology. Furthermore, azole resistance has be-
come a public health problem that needs continued inter-
national surveillance and research on the mechanisms that 
enable its selection in the environment. This report of the 
emergence of resistance has launched a new phase in the 
management of aspergillus diseases. Unless we can im-
plement measures that prevent the fungicide-driven route 
of resistance development, the clinical use of azoles will 
be severely compromised.
Acknowledgments
We thank Jan Zoll, Ton Rijs, Hein van der Lee, Diane Lamers-
Jansen, and Birgit Brandt for excellent technical assistance. We 
also thank Monica Slavin, Orla Morrissey, and Alison Campbell 
for local site support.
This work was supported in part by an unrestricted research 
grant through the Investigator Initiated Studies Program (IISP) 
of Merck, Sharp & Dohme (MSD). 
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	21,	No.	6,	June	2015	 1043
Figure 2.	Patient	characteristics	and	underlying	resistance	
mechanisms of patients with invasive and noninvasive 
Aspergillus	disease.	*Otomycosis,	dermatomycosis,	or	
onychomycosis;	1	patient	had	a	resistant	isolate	and	otomycosis	
(patient	9	in	the	online	Technical	Appendix	Table,	http://
wwwnc.cdc.gov/EID/article/21/6/14-0717-Techapp1.pdf).	†One	
patient	had	chronic	pulmonary	aspergillosis	and	ABPA.	‡Not	
classified	according	to	European	Organization	for	the	Research	
and	Treatment	of	Cancer/Mycoses	Study	Group	criteria	(5).	
§One	patient	is	included	with	46-bp	tandem-repeat	resistance	
mechanism.	ABPA,	allergic	bronchopulmonary	aspergillosis;	
CPA,	chronic	pulmonary	aspergillosis;	R,	resistant;	S,	
susceptible;	–,	negative;	+,	positive.
 
 
 
Table 1. Susceptibility	for	3	antifungal	medical	azoles	and	1	azole	fungicide	of	resistant	isolates	(60	isolates)	and	control	group	(60 
isolates)	after	species	identification 
Isolate 
Median	MIC,	mg/L 
Itraconazole Voriconazole Posaconazole Tebuconazole 
Azole-resistant Aspergillus fumigatus, n = 47 >8 2 1 8 
A. fumigatus sibling	species,*	n	=	13 1 2 0.25 >8 
A. fumigatus controls,	n	=	60 0.25 0.5 0.06 2 
*Aspergillus lentulus, Neosartorya pseudofischeri, N. udagawae. 
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Table 2. Acquired resistance mechanisms from each country in cyp51A gene	in	47	Aspergillus fumigatus isolates with an azole-
resistant phenotype 
Country 
No.	azole-resistant 
isolates,	n	=	47 
TR34/L98H	or	TR46/Y121F/T289A	
mechanism (no. isolates) Other mutations (no. isolates) 
No.	isolates without 
Cyp51A-mutations 
Austria 2 TR34/L98H	(2) 0 0 
Belgium 8 TR34/L98H	(7) F46Y/M172G	(1) 0 
Denmark 6 TR34/L98H	(4) 0 2 
France 4 TR34/L98H	(1) G54W	(1) 2 
Italy 5 TR34/L98H	(5) 0 0 
The	Netherlands 7 TR34/L98H	(4), 
TR46/Y121F/T289A	(3) 
0 0 
Spain 1 No	isolates 0 1 
Sweden 1 No	isolates F46Y/M172G 0 
United Kingdom 13 No	isolates P381R/D481E	(1),	L329V	(1),	
M220K	(1),	L77V/L399I/D481E	
(1),	M220I	(3),	M220R	(1),	
G54R	(1),	G54E	(1),	G54W	(1) 
2 
Resistant	isolates,	% 100 55.3 29.8 14.9 
  
